Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) have earned a consensus rating of “Moderate Buy” from the eight research firms that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $66.6667.

A number of research firms have commented on RVPH. Wall Street Zen raised Reviva Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, July 5th. Maxim Group lowered Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, April 8th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research report on Tuesday, April 21st.

Reviva Pharmaceuticals Price Performance

Shares of RVPH stock opened at $0.55 on Wednesday. The company has a market capitalization of $7.22 million, a price-to-earnings ratio of -0.14 and a beta of 0.47. Reviva Pharmaceuticals has a one year low of $0.26 and a one year high of $17.20. The company’s fifty day moving average price is $0.59 and its 200-day moving average price is $2.68.

Reviva Pharmaceuticals (NASDAQ:RVPH) last released its earnings results on Thursday, May 14th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.10). Equities research analysts expect that Reviva Pharmaceuticals will post -2.96 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC grew its holdings in Reviva Pharmaceuticals by 6.9% during the 2nd quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock valued at $171,000 after buying an additional 29,063 shares in the last quarter. NewEdge Advisors LLC purchased a new position in shares of Reviva Pharmaceuticals in the first quarter worth $58,000. XTX Topco Ltd lifted its holdings in shares of Reviva Pharmaceuticals by 63.6% in the fourth quarter. XTX Topco Ltd now owns 164,291 shares of the company’s stock worth $46,000 after buying an additional 63,893 shares in the last quarter. Lido Advisors LLC bought a new position in shares of Reviva Pharmaceuticals during the third quarter worth $37,000. Finally, Millennium Management LLC boosted its position in shares of Reviva Pharmaceuticals by 15.0% during the third quarter. Millennium Management LLC now owns 1,711,221 shares of the company’s stock worth $631,000 after acquiring an additional 223,178 shares during the last quarter. 63.18% of the stock is currently owned by institutional investors.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.